CJC-1295 With DAC

Growth Hormone Research Peptide for GHRH Receptor Activation & Long-Acting Endocrine Signalling

CJC-1295 with DAC is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It has attracted significant scientific interest due to its interaction with GHRH receptors and its role in research investigating growth hormone secretion, pituitary function and endocrine regulation.

The compound incorporates a Drug Affinity Complex (DAC) modification, designed to facilitate binding to circulating albumin and extend its duration of activity. This modification makes CJC-1295 with DAC particularly interesting in research examining prolonged hormonal signalling and growth hormone regulation.

Key Features

✓ Studied for its interaction with GHRH receptor pathways
✓ Incorporates Drug Affinity Complex (DAC) technology
✓ Investigated for prolonged growth hormone signalling
✓ Frequently researched in pituitary hormone regulation models
✓ Explored in hypothalamic and endocrine signalling research
✓ Relevant to growth hormone physiology and metabolic research

GHRH Receptor Research

CJC-1295 with DAC is investigated for its interaction with growth hormone-releasing hormone receptors. These receptors play an important role in regulating growth hormone secretion from the anterior pituitary gland.

Long-Acting Peptide Research

The DAC modification enables albumin binding, which extends the compound’s circulating half-life compared with shorter-acting GHRH analogues.

Researchers investigate this mechanism to understand prolonged peptide activity and sustained endocrine signalling.

Growth Hormone Signalling Research

Research explores how CJC-1295 with DAC influences growth hormone-related signalling pathways and the biological mechanisms involved in pituitary hormone secretion.

Endocrine Regulation Research

CJC-1295 with DAC is studied in models examining communication between the hypothalamus and pituitary gland and the hormonal pathways responsible for endocrine regulation.

Scientific Research Context

Growth hormone regulation involves a complex endocrine network connecting the hypothalamus, pituitary gland and peripheral tissues.

Growth hormone-releasing hormone (GHRH) is naturally produced by the hypothalamus and stimulates the anterior pituitary gland to release growth hormone.

CJC-1295 with DAC is a synthetic GHRH analogue incorporating a Drug Affinity Complex modification. This modification promotes reversible binding to serum albumin, extending its circulating half-life.

This makes it relevant to research investigating:

• • GHRH receptor signalling

• • Growth hormone secretion mechanisms

• • Pituitary gland activity

• • Albumin-binding peptide technology

• • Extended-duration hormonal signalling

• • Hypothalamic signalling pathways

• • Endocrine regulation

• • Somatotropic axis research

These research areas continue to contribute to scientific interest in CJC-1295 with DAC and its role in endocrine science.

Common Research Applications

CJC-1295 with DAC is investigated in research models involving:

• • Growth hormone-releasing hormone pathways

• • GHRH receptor activity

• • Pituitary hormone secretion

• • Growth hormone signalling

• • Albumin-binding peptide research

• • Extended peptide half-life mechanisms

• • Hypothalamic regulation

• • Endocrine physiology

Related Research Compounds

Researchers investigating growth hormone signalling and endocrine pathways may also study:

• • CJC-1295 No DAC – shorter-acting GHRH analogue research.

• • Ipamorelin – growth hormone secretagogue receptor signalling research.

• • GHRP-2 – growth hormone release and ghrelin receptor research.

• • GHRP-6 – growth hormone secretagogue and endocrine signalling research.

• • Sermorelin – GHRH analogue and pituitary hormone regulation research.

These compounds are investigated through different mechanisms within growth hormone and endocrine science.

Product Specifications

Product Name: CJC-1295 with DAC
Compound Type: Synthetic Peptide
Research Category: Growth Hormone & Endocrine Research
Primary Target: Growth Hormone-Releasing Hormone (GHRH) Receptor
Additional Feature: Drug Affinity Complex (DAC) Modification
Physical Form: Research Grade Powder
Available Sizes: 2mg, 5mg and 10mg Vials
Application: Scientific Research Use Only

Important Notice

For laboratory research use only. This product is intended solely for research, analytical and educational purposes. It is not intended for human or animal consumption, therapeutic use, veterinary use, diagnostic procedures or administration of any kind.

CJC-1295 with DAC is an experimental research peptide. Its safety and efficacy for human use have not been adequately established, and it should not be confused with CJC-1295 No DAC.